Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
MeSH Number(s)
D27.505.519.124.035
D27.505.954.248.150
D27.888.569.035.035
Concept/Terms
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Antineoplastic Alkylating Agents
- Alkylating Agents, Antineoplastic
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Antineoplastic Drugs
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastics
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 5 | 3 | 8 |
| 1997 | 3 | 7 | 10 |
| 1998 | 4 | 3 | 7 |
| 1999 | 3 | 6 | 9 |
| 2000 | 4 | 3 | 7 |
| 2001 | 6 | 5 | 11 |
| 2002 | 11 | 2 | 13 |
| 2003 | 11 | 3 | 14 |
| 2004 | 7 | 5 | 12 |
| 2005 | 10 | 6 | 16 |
| 2006 | 9 | 4 | 13 |
| 2007 | 9 | 6 | 15 |
| 2008 | 6 | 6 | 12 |
| 2009 | 7 | 8 | 15 |
| 2010 | 7 | 6 | 13 |
| 2011 | 9 | 13 | 22 |
| 2012 | 8 | 4 | 12 |
| 2013 | 20 | 5 | 25 |
| 2014 | 10 | 8 | 18 |
| 2015 | 13 | 6 | 19 |
| 2016 | 12 | 11 | 23 |
| 2017 | 14 | 5 | 19 |
| 2018 | 8 | 8 | 16 |
| 2019 | 10 | 6 | 16 |
| 2020 | 10 | 5 | 15 |
| 2021 | 1 | 1 | 2 |
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. Nat Biomed Eng. 2021 04; 5(4):346-359.
-
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021 02 04; 137(5):637-645.
-
Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
-
Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition. Pediatr Blood Cancer. 2021 02; 68(2):e28789.
-
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
-
Melflufen for relapsed and refractory multiple myeloma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1069-1078.
-
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J. 2020 09 01; 10(8):88.
-
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science. 2020 08 21; 369(6506):936-942.
-
Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2021 03; 35(3):916-919.
-
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.